Fig. 5: Aurora A stabilizes the YAP1 protein.

A Immunoblotting of YAP1, BCL-xL, TPX2, and phospho-Aurora A (pAURKA) in P1 and P4 hESCs. β-Actin was used as a loading control for equal protein concentrations. B Immunoblotting of YAP1, BCL-xL, and TPX2 in P4 hESCs 2 days after the introduction of control (siNC) and TPX2 (siTPX2) siRNA. β-Actin was used as a loading control for equal protein concentrations. C Immunoblotting of YAP1 in P1 or P4 hESCs after 200 μg/ml cycloheximide (CHX) treatment, with β-actin as a loading control for equal protein concentrations. D Immunoblotting for YAP1 or TPX2 after treatment with the indicated dose of Dox for 24 h (arrow for induced GFP-TPX2, * for endogenous TPX2). α-Tubulin was utilized for equal protein loading. E The relative levels of TPX2 or YAP1 mRNA in iTPX2-hESCs after treatment with the indicated dose of Dox for 24 h. F Immunoblotting of YAP1, TPX2, and phospho-Aurora A (pAURKA) after 24 h treatment with 0.1 μg/ml Dox. G Immunoblotting of YAP1 in iTPX2-hESCs with or without 0.1 μg/ml Dox for the indicated time after treatment with 200 μg/ml CHX. β-Actin was utilized as a loading control for equal protein concentrations (top). Graph of the normalized band intensity (n = 4 independent experiments; mean ± SEM, two-way ANOVA, ***p < 0.001, bottom).